Quantum Biopharma (QNTM) Return on Capital Employed (2024 - 2026)

Quantum Biopharma has disclosed Return on Capital Employed across 3 years of filings, most recently posting 450.31% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 450.31%, up 68255.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 450.31% (up 68255.0% YoY), and the FY2025 annual result was 189.34%, down 3737.0% from the prior year.
• Return on Capital Employed came in at 450.31% for Q1 2026 at Quantum Biopharma, up from 231.9% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 450.31% in Q1 2026 to a low of 791.35% in Q2 2025.
• The 3-year median for Return on Capital Employed is 208.91% (2025), against an average of 182.72%.
• Across the five-year window, Return on Capital Employed sank 12670 bps in 2025 and jumped 68255 bps in 2026, its largest moves.
• Quantum Biopharma's Return on Capital Employed stood at 105.2% in 2024, then sank by 120 bps to 231.9% in 2025, then jumped by 294 bps to 450.31% in 2026.
• The last three Return on Capital Employed figures came in at 450.31% (Q1 2026), 231.9% (Q4 2025), and 185.93% (Q3 2025), per Business Quant data.